Lieke H.H. Meeter
VU University Amsterdam
Publications 33
#1Katrina M. Moore (UCL: University College London)H-Index: 1
#2Jennifer M. Nicholas (Lond: University of London)H-Index: 20
Last.Daniel H. GeschwindH-Index: 129
view all 171 authors...
Summary Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. Methods In this international, retrospective cohort study, we col...
#1Emma L. van der Ende (EUR: Erasmus University Rotterdam)H-Index: 4
#2Lieke H.H. Meeter (EUR: Erasmus University Rotterdam)H-Index: 8
Last.John C. van Swieten (EUR: Erasmus University Rotterdam)H-Index: 53
view all 43 authors...
Summary Background Neurofilament light chain (NfL) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN, C9orf72, and MAPT. A better understanding of NfL dynamics is essential for upcoming therapeutic trials. We aimed to study longitudinal NfL trajectories in people with presymptomatic and symptomatic genetic frontotemporal dementia. Methods We recruited participants from 14 centres collaborating in the Geneti...
2 CitationsSource
#1Lieke H.H. Meeter (EUR: Erasmus University Rotterdam)H-Index: 8
#2Rebecca M. E. Steketee (EUR: Erasmus University Rotterdam)H-Index: 7
Last.John VanSwieten (EUR: Erasmus University Rotterdam)H-Index: 71
view all 47 authors...
Background: Semantic dementia (SD) is a neurodegenerative disorder characterised by progressive language problems falling within the clinicopathological spectrum of frontotemporal lobar degeneration (FTLD). The development of disease-modifying agents may be facilitated by the relative clinical and pathological homogeneity of SD, but we need robust monitoring biomarkers to measure their efficacy. In different FTLD subtypes, neurofilament light chain (NfL) is a promising marker, therefore we inves...
1 CitationsSource
#1Claire Bridel (VU: VU University Amsterdam)H-Index: 5
#2Wessel N. van Wieringen (VU: VU University Amsterdam)H-Index: 22
Last.Edward J. Wild (UCL Institute of Neurology)H-Index: 27
view all 77 authors...
textabstractImportance: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date. Objectives: To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating...
9 CitationsSource
#1Oskar Hansson (Lund University)H-Index: 64
#2Alexander Frizell Santillo (Lund University)H-Index: 11
Last.Shorena Janelidze (Lund University)H-Index: 22
view all 9 authors...
textabstractObjective: Diagnosis of frontotemporal dementia (FTD) is complicated by the overlap of clinical symptoms with other dementia disorders. Development of robust fluid biomarkers is critical to improve the diagnostic work-up of FTD. Methods: CSF concentrations of placental growth factor (PlGF) were measured in the discovery cohort including patients with FTD (n = 27), Alzheimer disease (AD) dementia (n = 75), DLB or PDD (n = 47), subcortical vascular dementia (VaD, n = 33), mild cognitiv...
#1Timothy Rittman (University of Cambridge)H-Index: 19
#2Robin J Borchert (University of Cambridge)H-Index: 4
Last.Miren ZulaicaH-Index: 2
view all 125 authors...
The presymptomatic phase of neurodegenerative diseases are characterized by structural brain changes without significant clinical features. We set out to investigate the contribution of functional network resilience to preserved cognition in presymptomatic genetic frontotemporal dementia. We studied 172 people from families carrying genetic abnormalities in C9orf72, MAPT, or PGRN. Networks were extracted from functional MRI data and assessed using graph theoretical analysis. We found that despit...
3 CitationsSource
#1Enrico Premi (University of Brescia)H-Index: 18
#2Vince D. Calhoun (UNM: University of New Mexico)H-Index: 93
Last.Miren ZulaicaH-Index: 2
view all 133 authors...
Abstract Frontotemporal Dementia (FTD) is preceded by a long period of subtle brain changes, occurring in the absence of overt cognitive symptoms, that need to be still fully characterized. Dynamic network analysis based on resting-state magnetic resonance imaging (rs-fMRI) is a potentially powerful tool for the study of preclinical FTD. In the present study, we employed a "chronnectome" approach (recurring, time-varying patterns of connectivity) to evaluate measures of dynamic connectivity in 4...
2 CitationsSource
The frontotemporal dementia (FTD) spectrum is a heterogeneous group of neurodegenerative syndromes with overlapping clinical, molecular and pathological features, all of which challenge the design of clinical trials in these conditions. To date, no pharmacological interventions have been proven effective in significantly modifying the course of these disorders. This study critically reviews the construct and methodology of previously published randomised controlled trials (RCTs) in FTD spectrum ...
2 CitationsSource
#1Emma L. van der Ende (EUR: Erasmus University Rotterdam)H-Index: 4
#2Lieke H.H. Meeter (EUR: Erasmus University Rotterdam)H-Index: 8
Last.John VanSwieten (EUR: Erasmus University Rotterdam)H-Index: 71
view all 19 authors...
textabstractObjective: To identify novel CSF biomarkers in GRN-associated frontotemporal dementia (FTD) by proteomics using mass spectrometry (MS). Methods: Unbiased MS was applied to CSF samples from 19 presymptomatic and 9 symptomatic GRN mutation carriers and 24 noncarriers. Protein abundances were compared between these groups. Proteins were then selected for validation if identified by ≥4 peptides and if fold change was ≤0.5 or ≥2.0. Validation and absolute quantification by parallel reacti...
#1Jessica L. Panman (EUR: Erasmus University Rotterdam)H-Index: 5
#2Lize C. Jiskoot (EUR: Erasmus University Rotterdam)H-Index: 9
Last.Janne M. Papma (EUR: Erasmus University Rotterdam)H-Index: 9
view all 13 authors...
Abstract In genetic frontotemporal dementia, cross-sectional studies have identified profiles of presymptomatic neuroanatomical loss for C9orf72 repeat expansion, MAPT, and GRN mutations. In this study, we characterize longitudinal gray matter (GM) and white matter (WM) brain changes in presymptomatic frontotemporal dementia. We included healthy carriers of C9orf72 repeat expansion (n = 12), MAPT (n = 15), GRN (n = 33) mutations, and related noncarriers (n = 53), that underwent magnetic resonanc...
4 CitationsSource